Revenue (Quarterly) Chart

Historical Revenue (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2019 31.95M
September 30, 2019 41.44M
June 30, 2019 51.41M
March 31, 2019 54.16M
December 31, 2018 38.31M
September 30, 2018 44.61M
June 30, 2018 48.05M
March 31, 2018 45.51M
December 31, 2017 35.44M
September 30, 2017 39.22M
June 30, 2017 43.48M
March 31, 2017 42.99M
December 31, 2016 33.32M
September 30, 2016 36.76M
June 30, 2016 38.77M
March 31, 2016 37.29M
December 31, 2015 24.14M
September 30, 2015 34.60M
June 30, 2015 38.08M
March 31, 2015 33.57M
December 31, 2014 24.26M
September 30, 2014 31.11M
June 30, 2014 36.31M
March 31, 2014 30.26M
December 31, 2013 24.53M
Date Value
September 30, 2013 29.53M
June 30, 2013 32.04M
March 31, 2013 26.71M
December 31, 2012 27.55M
September 30, 2012 29.44M
June 30, 2012 28.88M
March 31, 2012 25.64M
December 31, 2011 25.88M
September 30, 2011 28.09M
June 30, 2011 25.52M
March 31, 2011 26.06M
December 31, 2010 25.71M
September 30, 2010 23.35M
June 30, 2010
March 31, 2010 21.46M
December 31, 2009 22.88M
September 30, 2009 22.98M
June 30, 2009 20.99M
March 31, 2009 18.57M
December 31, 2008 23.55M
September 30, 2008 22.30M
June 30, 2008 22.01M
March 31, 2008 18.36M
December 31, 2007 22.73M
September 30, 2007 20.20M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 15.26B
ANI Pharmaceuticals, Inc. 266.04M
Corcept Therapeutics, Inc. 256.15M
Veru, Inc. 0.00
Avadel Pharmaceuticals Plc 77.47M

Revenue (Quarterly) Related Metrics